SCHEMBL6892716

SCHEMBL6892716

C[CH]OC(=O)Oc1ccc(CC)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.47
POLB P06746 1/20 0.46
ALDH1A1 P00352 3/20 0.44
THRB P10828 2/20 0.44
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 2/20 0.40
MAOB P27338 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 2/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
ELANE P08246 1/20 0.40
MEN1 O00255 1/20 0.39
HSP90AA1 P07900 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL47952 0.85 RAB9A (0.56) RAB9APOLBALDH1A1THRBRXRA
SCHEMBL238518 0.79 RAB9A (0.51) RAB9APOLBALDH1A1THRBRXRA
SCHEMBL14887376 0.79 RAB9A (0.56) RAB9APOLBALDH1A1THRBRXRA
SCHEMBL6890425 0.79 LMNA (0.55) ALDH1A1CYP2C19LMNAMAPTKMT2A
SCHEMBL6894569 0.79 CES2 (0.47) RAB9AALDH1A1THRBSMN1; SMN2CYP2C19
SCHEMBL17473063 0.78 LMNA (0.53) RAB9APOLBALDH1A1RXRARXRB
SCHEMBL1788228 0.78 RAB9A (0.50) RAB9APOLBALDH1A1THRBRXRA
SCHEMBL368214 0.78 RAB9A (0.63) RAB9APOLBALDH1A1RXRARXRB
SCHEMBL17637684 0.78 RAB9A (0.50) RAB9APOLBALDH1A1THRBRXRA
SCHEMBL14610166 0.77 POLB (0.62) RAB9APOLBALDH1A1THRBRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 RAB9A 1538/4885POLB 2952/4885ALDH1A1 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.